指南与共识支持与姑息治疗

CAN.HEAL联盟关于分子肿瘤委员会(MTB)的十条建议

A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium.
指南 / 共识 · Eur J Cancer · 2025-04-14

CAN.HEAL联盟由17个欧盟国家的47家癌症中心与学术机构组成,通过两年协作和七次专门线上会议,针对分子肿瘤委员会(MTB)缺乏标准化指南的问题,在10个关键领域形成共识性建议,涉及MTB的核心职能、组成、患者入选标准、知情同意、信息技术工作流程、报告规范与培训等。

要点

  • MTB的首要职能是为需要超出标准治疗范围照护的患者进行分子与临床评估。
  • MTB核心组成应包括肿瘤内科医生、分子生物学家、病理学家和生物信息学人员。
  • 建议采用包含最小与最大数据集的两级信息技术工作流程,并配套综合决策支持工具。

核心结论

  • 标准化MTB实践是朝向公平获取个体化医疗、改善欧洲癌症照护的关键一步。
  • 可持续实施需要欧盟层面的协调努力,以及能在真实世界环境中持续优化基因组驱动决策的动态MTB。

研究设计与样本

  • CAN.HEAL联盟由17个欧盟国家的47家癌症中心与学术机构组成,通过两年协作和七次专门线上会议形成共识性建议,覆盖10个关键领域。

主要发现

  • 联盟认为MTB的首要职能是为需要超出标准治疗范围照护的患者进行分子与临床评估。
  • MTB核心组成应包括肿瘤内科医生、分子生物学家、病理学家和生物信息学人员。
  • 患者入选标准应优先考虑体能状态,并对罕见病例保留灵活性。
  • 建议采用含最小与最大数据集的两级信息技术工作流程,并配套综合决策支持工具。
  • 建议关注基因组检测,承认NGS检测方法的多样性并提出通用指导原则。

关键数值与推荐

  • 建议MTB报告应简洁,技术细节在分子诊断报告中提供。
  • 共享知情同意对样本采集、数据使用和研究至关重要。
  • 创新方法如药物再发现方案(Drug Rediscovery Protocol)支持获取超说明书用药治疗。
  • 对MTB成员的统一培训对弥合这一发展领域中的知识差距至关重要。
  • 需要指标以随时间评估MTB的有效性。

临床怎么用

  • 原文未据此给出针对具体临床操作的推荐;建议内容为MTB组织与流程层面的共识,包括核心组成、入选标准、两级信息技术工作流程、简洁报告及统一培训。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The CAN.HEAL consortium, comprising 47 cancer centers and academic institutions across 17 EU countries, has developed a set of recommendations for Molecular Tumor Boards (MTBs) to address the lack of standardized guidelines in personalized cancer medicine. METHODS: Over the past 2 years, through extensive collaboration and seven dedicated online meetings, CAN.HEAL experts developed consensus-based recommendations across 10 critical domains. RESULTS: The consortium agreed that MTBs' primary role is to perform molecular and clinical assessments for patients requiring care beyond standard treatment. Core MTB composition should include medical oncologists, molecular biologists, pathologists, and bioinformaticians. Patient eligibility criteria should prioritize performance status, with flexibility for rare cases. Shared informed consent is crucial for sample collection, data use, and research. A two-tiered IT workflow, with minimal and maximal datasets, is recommended, along with a comprehensive decision support tool. These recommendations focus on genomic testing, acknowledging diversity of NGS assays and proposing general guidelines. MTB reports should be concise, with technical details provided in the molecular diagnostic report. Innovative approaches like the Drug Rediscovery Protocol support access to off-label therapies. Harmonized training for MTB members is essential to bridging knowledge gaps in this evolving field. Indicators are needed to assess MTB effectiveness over time. Expanding MTB benefits to underserved populations depends on creating a shared European MTB database. CONCLUSION: Standardizing MTB practices represents a key step toward equitable access to personalized medicine and improved cancer care across Europe. Sustainable implementation requires coordinated EU efforts, and dynamic MTBs that continuously refine genomic-driven decisions within real-world contexts.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ciliberto G, De Maria R, Giacomini P, et al. A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium. Eur J Cancer. 2025. PMID: 40253820. doi:10.1016/j.ejca.2025.115433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。